연구성과로 돌아가기

2023 연구성과별 연구자 정보 (1323 / 2675)

※ 현재 Web of Science 저자 정보만 집계되어 있습니다.
※ 컨트롤 + 클릭으로 열별 다중 정렬 가능합니다.
Excel 다운로드
Document Title Author Full Name Author Short Name Index Corresponding Address ResearcherID ResearcherID Author Name ORCID ORCID Author Name Related Email
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Skarbnik, Alan P. Skarbnik, AP 6 Novant Hlth Canc Inst, Charlotte, NC USA dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Yakoub-Agha, Ibrahim Yakoub-Agha, I 7 Univ Lille, CHU Lille, INSERM U1286, Infinite, Lille, France R-7872-2018 Yakoub-Agha, Ibrahim 0000-0003-4524-8782 Yakoub-Agha, Ibrahim dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Ko, Bor-Sheng Ko, BS 8 Natl Taiwan Univ Hosp, Dept Internal Med, Taipei, Taiwan dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Bruno, Benedetto Bruno, B 9 K-1392-2018 Bruno, Benedetto 0000-0002-7299-6770 Bruno, Benedetto dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Waller, Edmund K. Waller, EK 10 AAP-3055-2020 Waller, Edmund 0000-0003-0816-6729 Waller, Edmund K. dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Yared, Jean Yared, J 11 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Sohn, Sang Kyun Sohn, SK 12 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Bulabois, Claude-Eric Bulabois, CE 13 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Teshima, Takanori Teshima, T 14 G-1671-2012 teshima, takanori dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Jacobsohn, David Jacobsohn, D 15 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Greinix, Hildegard Greinix, H 16 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Mokatrin, Ahmad Mokatrin, A 17 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Lee, Yihua Lee, YH 18 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Wahlstrom, Justin T. Wahlstrom, JT 19 dmiklos@stanford.edu;
Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study Styles, Lori Styles, L 20 dmiklos@stanford.edu;
페이지 이동: